CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and

Cancer Cell biology Molecular biology

Journal

iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038

Informations de publication

Date de publication:
19 Jul 2024
Historique:
received: 17 05 2023
revised: 05 04 2024
accepted: 11 05 2024
medline: 18 7 2024
pubmed: 18 7 2024
entrez: 18 7 2024
Statut: epublish

Résumé

High-grade serous ovarian cancers (HGSOCs) with homologous recombination deficiency (HRD) are initially responsive to poly (ADP-ribose) polymerase inhibitors (PARPi), but resistance ultimately emerges. HGSOC with

Identifiants

DOI: 10.1016/j.isci.2024.109978 PMID: 39021796 PMC: PMC11253285
pubmed: 39021796
doi: 10.1016/j.isci.2024.109978
pii: S2589-0042(24)01200-8
pmc: PMC11253285
doi:

Types de publication

Journal Article

Langues

eng

Pagination

109978

Informations de copyright

© 2024 Published by Elsevier Inc.

Déclaration de conflit d'intérêts

F.S. declared scientific advisory board for AstraZeneca, REPARE Therapeutics, GSK, and Zentalis, and Grant/Research support from AstraZeneca for support for clinical trial, and REPARE Therapeutics, Sierra Oncology and support preclinical research. C.L.S. declares Advisory Boards for Sierra Oncology, AstraZeneca, Clovis Oncology, Roche, Eisai Inc, Takeda, MSD, and Illumina, and Grant/Research support from Sierra Oncology, Clovis Oncology, Eisai Inc, Roche, Beigene, AstraZeneca, and Boehringer Ingelheim. B.S., S.M., and C.H. are employees of Sierra Oncology or were employees of Sierra Oncology while they were involved with this work and have stock and/or stock interests in Sierra Oncology. Other authors declare no conflicts of interest.

Auteurs

Haineng Xu (H)

Ovarian Cancer Research Center, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Sarah B Gitto (SB)

Ovarian Cancer Research Center, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Department of Pathology and Laboratory Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Gwo-Yaw Ho (GY)

The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
Department of Medical Biology, University of Melbourne, Parkville, VIC 3010, Australia.

Sergey Medvedev (S)

Ovarian Cancer Research Center, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Kristy Shield-Artin (K)

The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
Department of Medical Biology, University of Melbourne, Parkville, VIC 3010, Australia.

Hyoung Kim (H)

Ovarian Cancer Research Center, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Sally Beard (S)

The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.

Yasuto Kinose (Y)

Ovarian Cancer Research Center, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Xiaolei Wang (X)

Ovarian Cancer Research Center, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Holly E Barker (HE)

The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
Department of Medical Biology, University of Melbourne, Parkville, VIC 3010, Australia.

Gayanie Ratnayake (G)

The Royal Women's Hospital, Parkville, VIC 3052, Australia.

Wei-Ting Hwang (WT)

Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA 19104, USA.

Ryan J Hansen (RJ)

Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, NSW 2145, Australia.

Bryan Strouse (B)

Sierra Oncology, Inc, 885 West Georgia Street, Suite 2150, Vancouver, BC V6C 3E8, Canada.

Snezana Milutinovic (S)

Sierra Oncology, Inc, 885 West Georgia Street, Suite 2150, Vancouver, BC V6C 3E8, Canada.

Christian Hassig (C)

Sierra Oncology, Inc, 885 West Georgia Street, Suite 2150, Vancouver, BC V6C 3E8, Canada.

Matthew J Wakefield (MJ)

The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, VIC 3010, Australia.

Cassandra J Vandenberg (CJ)

The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
Department of Medical Biology, University of Melbourne, Parkville, VIC 3010, Australia.

Clare L Scott (CL)

The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
Department of Medical Biology, University of Melbourne, Parkville, VIC 3010, Australia.
The Royal Women's Hospital, Parkville, VIC 3052, Australia.
Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, VIC 3010, Australia.
Sir Peter MacCallum Cancer Centre Department of Oncology, University of Melbourne, Parkville, VIC 3010, Australia.

Fiona Simpkins (F)

Ovarian Cancer Research Center, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Classifications MeSH